EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer

Etienne J Slapak, Mouad El Mandili, Marieke S Ten Brink, Alexander Kros, Maarten F Bijlsma, C Arnold Spek

Cancer Letters · 2024-05 · 590 · 216845

DOI: 10.1016/j.canlet.2024.216845 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-05. Verfasst von Etienne J Slapak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC Location University of Amsterdam, Center of Experimental and Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands; Cancer Cen…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Silicon Dioxide, Paclitaxel, Nanoparticles. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Couch Foundation, KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic adenocarcinoma (PDAC) is highly resistant to conventional chemotherapeutic interventions, resulting in exceptionally low survival rates. The limited efficacy can in part be attributed to dose limitations and treatment cessation urged by toxicity of currently used chemotherapy. The advent of targeted delivery strategies has kindled hope for circumventing off-target toxicity. We have previously reported a PDAC-specific mesoporous silica nanoparticle (MSN) containing a protease linker responsive to ADAM9, a PDAC-enriched extracellularly deposited protease. Upon loading with paclitaxel these ADAM9-MSNs reduced side effects both in vitro and in vivo, however, disappointing antitumor efficacy was observed in vivo. Here, we propose that an efficient uptake of MSNs by tumor cells might underlie the lack of antitumor efficacy of MSNs functionalized with linker responsive to extracellular proteases. Harnessing this premise to improve antitumor efficacy, we performed an in silico analysis to identify PDAC-enriched intracellular proteases. We report the identification of BACE2, CAPN2 and DPP3 as PDAC enriched intracellular proteases, and report the synthesis of BACE2-, CAPN2- and DPP3-responsive MSNs. Extensive preclinical assessments revealed that paclitaxel-loaded CAPN2- and DPP3-MSNs exhibit high PDAC specificity in vitro as opposed to free paclitaxel. The administration of paclitaxel-loaded CAPN2- and DPP3-MSNs in vivo confirmed the reduction of leukopenia and induced no organ damage. Promisingly, in two mouse models CAPN2-MSNs reduced tumor growth at least as efficiently as free paclitaxel. Taken together, our results pose CAPN2-MSNs as a promising nanocarrier for the targeted delivery of chemotherapeutics in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsSilicon DioxidePaclitaxelNanoparticlesCalpainDrug CarriersHumansAnimalsCell Line, TumorXenograft Model Antitumor AssaysMicePorosityAmyloid Precursor Protein SecretasesMice, NudeFemale

Stichwörter der Autor:innen

ADAM9AntitumorBACE2CAPN2DPP3Drug deliveryLeukopeniaMSNNeurotoxicityPDACTargeted therapy

Substanzen

Silicon DioxidePaclitaxelCalpainDrug CarriersCAPN2 protein, humanAmyloid Precursor Protein Secretases

Autor:innen und Institutionen

  • Amsterdam UMC Location University of Amsterdam, Center of Experimental and Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Biology, Amsterdam, the Netherlands. Electronic…
  • Amsterdam UMC Location University of Amsterdam, Center of Experimental and Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: m.elmandili@amsterdamumc.nl.
  • Amsterdam UMC Location University of Amsterdam, Center of Experimental and Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: m.s.tenbrink@amsterdamumc.nl.
  • Department of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands. Electronic address: a.kros@chem.leidenuniv.nl.

Förderung

  • Cancer Couch Foundation
  • KWF Kankerbestrijding

Zitieren

APA

Slapak, E. J., El Mandili, M., Ten Brink, M. S., Kros, A., Bijlsma, M. F., & Spek, C. A. (2024). CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer. Cancer Letters, 590, 216845. https://doi.org/10.1016/j.canlet.2024.216845

Vancouver

Slapak EJ, El Mandili M, Ten Brink MS, Kros A, Bijlsma MF, Spek CA. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer. Cancer Letters. 2024;590:216845. doi:10.1016/j.canlet.2024.216845

BibTeX
@article{Slapak2024,
  author = {Slapak, Etienne J and El Mandili, Mouad and Ten Brink, Marieke S and Kros, Alexander and Bijlsma, Maarten F and Spek, C Arnold},
  title = {CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer},
  journal = {Cancer Letters},
  year = {2024},
  volume = {590},
  pages = {216845},
  doi = {10.1016/j.canlet.2024.216845}
}
Kostenlos starten →